Orforglipron, an oral GLP-1 receptor agonist, maintained 74.7% of weight reduction in participants previously treated with tirzepatide and 79.3% in those treated with semaglutide, compared to only 37-49% maintenance with placebo over 52 weeks. This represents a breakthrough in obesity treatment continuity, addressing a critical gap in weight management therapy. The oral formulation could dramatically improve treatment adherence compared to weekly injections, potentially expanding access to effective obesity treatment globally. However, this maintenance study reveals an inherent vulnerability in GLP-1 therapy—without ongoing treatment, patients regain substantial weight regardless of the initial medication used. The trial's design also raises questions about optimal transition strategies, as participants weren't compared against continuing their original injectable therapy. While the gastrointestinal side effects mirror those of other GLP-1 agonists, the convenience factor could prove transformative for long-term obesity management. This represents incremental but meaningful progress in making sustained weight loss more achievable, though the fundamental requirement for lifelong medication remains unchanged.